Navigation Links
Femasys and Norgenix Announce Distribution Agreement for Groundbreaking New Device for Infertility Diagnosis
Date:8/16/2011

SPARTANBURG, S.C., Aug. 16, 2011 /PRNewswire/ -- Femasys Inc. and Norgenix Pharmaceuticals, LLC today announced an agreement for exclusive distribution rights in the United States as well as US territories and military bases for Femasys' FemVue™ Saline-Air Device. This FDA cleared device is used to evaluate a woman's fallopian tubes with standard ultrasound, called a Sono HSG. Femasys Inc. is an emerging medical device developer of women's healthcare solutions. Norgenix Pharmaceuticals, LLC, a wholly owned subsidiary of the J M Smith Corporation, is a North American distributor with a world-class sales channel for medical device and pharmaceutical products in the women's health arena. Norgenix is licensed to sell, market, and distribute medical devices and prescription drug products in all 50 US states.

"Our agreement with Norgenix is anticipated to have an immediate and significant impact on our sales expansion efforts as we offer the market an advancement in diagnostic care for an infertile woman," stated Kathy Lee-Sepsick, President & CEO of Femasys Inc. "The Norgenix team is providing us with multiple ready-made relationships; we are excited to ramp our production to meet the numerous opportunities Norgenix has presented."

The FemVue™ Saline-Air Device has been cleared by the FDA for use during diagnostic Sono HSG for fallopian tube evaluations. It creates a consistent alternating pattern of saline and air used as contrast allowing physicians to evaluate a woman's fallopian tubes with existing ultrasound equipment. With the FemVue pattern of saline and air, Sono HSG can be a reliable, cost-effective, convenient, and safe procedure performed quickly by a woman's gynecologist or infertility specialist in the office.

"We are pleased to announce our partnership with Femasys," stated Ken Couch, President of Norgenix Pharmaceuticals, LLC. "Femasys' FemVue device is an innovative product that perfectly aligns with our strategic mission to offer solutions to unmet needs in women's health."

"FemVue is an innovative solution in providing convenient and reliable evaluation of the fallopian tubes to the estimated 10 million women in the United States today, including those struggling with infertility or suffering from female fallopian tube disorders," stated Michael Rackley, COO & Senior Vice President of Norgenix Pharmaceuticals. "We are very optimistic about the potential for FemVue; we expect to expand the market rapidly."

ABOUT FEMASYS INC. | www.femasys.com

ABOUT NORGENIX | www.norgenixpharma.com

Media Contact:
Sims Hammond, 864.580.2350, Sims@LaunchSomething.com


'/>"/>
SOURCE Norgenix Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011
2. Beacon Enterprise Solutions Announces $3.4 Million Contract Award With the Veterans Administration
3. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
4. 3SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results
5. NewCardio Announces Financial Results for Its 2011 Second Quarter
6. Dehaier Medical Announces Record Second Quarter 2011 Financial Results
7. Emdeon Announces Support for Electronic Prescribing of Controlled Substances Using the DEA-Allowed Quicker-to-Market Approach
8. Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results
9. GeoVax Labs, Inc. Announces Second Quarter Financial Results
10. Global Pharm Holdings Group, Inc. Announces Second Quarter 2011 Financial Results
11. Spherix Announces Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2017)... Inc., a biotechnology company focused on the development of novel ... and Head of Virology Kristin Bedard has been invited to ... Beyond meeting sponsored by Life Science Washington.  This Symposium ... PDT at the Agora Conference Center in Seattle, ... joined by other leaders in infectious disease research and the ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 More ... a further effort to help spread lessons learned from ... the International Diabetes Federation (IDF) and Eli Lilly and ... for the second phase of the Bringing Research in ... reaffirming their commitment to helping people with diabetes effectively ...
(Date:6/7/2017)... 2017 Endo International plc (NASDAQ: ... Hon. Joseph R. Goodwin , U.S. District Court ... Virginia , entered a case management order in ... Products Liability Litigation (the "MDL") that includes a provision ... expert disclosures on specific causation within one hundred twenty ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... ... Harbour , a DAO (decentralized autonomous organization) that harnesses the wisdom of ... technical specifications . , 2017 has seen an explosion of token launches by blockchain ... will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, said, “We ...
(Date:6/27/2017)... ... June 27, 2017 , ... From June 20-22, EarQ ... was held in Syracuse, New York, where EarQ is headquartered. , Together, the ... to connect with today’s savvy consumer, and the latest in hearing technology. At ...
(Date:6/27/2017)... ... June 27, 2017 , ... PR News is looking ... studies guidebook. This guidebook offers an excellent branding and exposure opportunity for the ... studies and how-to’s that fall into the following categories:, , ...
(Date:6/27/2017)... ... June 27, 2017 , ... Hammer Strength, the world’s leading performance ... Javair Gillett of the Houston Rockets the NBSCA Strength & Conditioning Coach of the ... by NBSCA members who vote to select the coach who embodies the highest level ...
(Date:6/27/2017)... Washington DC (PRWEB) , ... June 27, 2017 , ... ... Report Best Children’s Hospitals rankings, with its Neonatology program ranking #1 out of ... was also named to the coveted Honor Roll, a distinction given to the ...
Breaking Medicine News(10 mins):